WIXOM, Mich., July 30, 2018 /PRNewswire/ -- Rockwell Medical,
Inc. (NASDAQ:RMTI) (the "Company") today announced that the Audit Committee of its Board of Directors has engaged Marcum
LLP as Rockwell Medical's new independent registered public accounting firm.
The Audit Committee of the Rockwell Medical Board engaged Marcum LLP following a month-long search and evaluation of several
audit firms.
The Company has also filed a Form 8-K with the Securities and Exchange Commission noting the engagement of Marcum LLP.
About Rockwell Medical, Inc.
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney
disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.
Rockwell's anemia drug Triferic is the only FDA-approved product indicated for iron replacement and maintenance of hemoglobin
in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the
delivery mechanism. Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and
maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in
the U.S. dialysis market and other major markets globally.
Rockwell's FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol
(active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has
been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an
improvement in renal osteodystrophy. Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis
market.
Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to
dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell's products
are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream.
Rockwell has three U.S. manufacturing/distribution facilities.
Rockwell's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of
dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and
improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for
indications outside of hemodialysis. Please visit www.rockwellmed.com for more information.
Forward-Looking Statement
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal
securities laws, including, but not limited to, Rockwell's intention to bring to market Triferic and Calcitriol. Words such as
"may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "plan," "potential,"
"predict," "forecast," "project," "plan", "intend" or similar expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While Rockwell believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date
of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various
risks and uncertainties (including without limitation those set forth in Rockwell's SEC filings), many of which are beyond
our control and subject to change Actual results could be materially different. Risks and uncertainties include: the ongoing
litigation with Rockwell's former Chief Executive Officer, Chief Financial Officer and certain current and former directors; the
timing for the appointment of a successor Chief Executive Officer, Chief Financial Officer; Rockwell's ability to maintain
compliance with SEC and NASDAQ rules and requests; and whether Rockwell can successfully execute on its business strategy.
Rockwell expressly disclaims any obligation to update or alter any statements whether as a result of new information, future
events or otherwise, except as required by law.
Contacts
Dan Katcher / Kelly Sullivan / Arielle
Rothstein
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
View original content:http://www.prnewswire.com/news-releases/rockwell-medical-announces-engagement-of-marcum-llp-as-new-independent-auditor-300688369.html
SOURCE Rockwell Medical, Inc.